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Abstract
OBJECTIVES: To learn upon incidence, underlying mechanisms and effectiveness of treatment strategies in patients with central airway
and pulmonary parenchymal aorto-bronchial ﬁstulation after thoracic endovascular aortic repair (TEVAR).
METHODS: Analysis of an international multicentre registry (European Registry of Endovascular Aortic Repair Complications) between
2001 and 2012 with a total caseload of 4680 TEVAR procedures (14 centres).
RESULTS: Twenty-six patients with a median age of 70 years (interquartile range: 60–77) (35% female) were identiﬁed. The incidence of
either central airway (aorto-bronchial) or pulmonary parenchymal (aorto-pulmonary) ﬁstulation (ABPF) in the entire cohort after TEVAR in
the study period was 0.56% (central airway 58%, peripheral parenchymal 42%). Atherosclerotic aneurysm formation was the leading indica-
tion for TEVAR in 15 patients (58%). The incidence of primary endoleaks after initial TEVAR was n = 10 (38%), of these 80% were either type
I or type III endoleaks. Fourteen patients (54%) developed central left bronchial tree lesions, 11 patients (42%) pulmonary parenchymal
lesions and 1 patient (4%) developed a tracheal lesion. The recognized mechanism of ABPF was external compression of the bronchial tree
in 13 patients (50%), the majority being due to endoleak formation, further ischaemia due to extensive coverage of bronchial feeding ar-
teries in 3 patients (12%). Inﬂammation and graft erosion accounted for 4 patients (30%) each. Cumulative survival during the entire study
period was 39%. Among deaths, 71% were attributed to ABPF. There was no difference in survival in patients having either central airway
or pulmonary parenchymal ABPF (33 vs 45%, log-rank P = 0.55). Survival with a radical surgical approach was signiﬁcantly better when
compared with any other treatment strategy in terms of overall survival (63 vs 32% and 63 vs 21% at 1 and 2 years, respectively), as well as
in terms of ﬁstula-related survival (63 vs 43% and 63 vs 43% at 1 and 2 years, respectively).
†The ﬁrst two authors contributed equally to this work.
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CONCLUSIONS: ABPF is a rare but highly lethal complication after TEVAR. The leading mechanism behind ABPF seems to be a continuing
external compression of either the bronchial tree or left upper lobe parenchyma. In this setting, persisting or newly developing endoleak
formation seems to play a crucial role. Prognosis does not differ in patients with central airway or pulmonary parenchymal ﬁstulation.
Radical bronchial or pulmonary parenchymal repair in combination with stent graft removal and aortic reconstruction seems to be the
most durable treatment strategy.
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INTRODUCTION
Since its broad introduction in the late 1990s, thoracic endovascular
aortic repair (TEVAR) has gained widespread acceptance for the
treatment of various types of acute and chronic thoracic aortic
pathology [1–3]. However, as indications were further broadened,
several limitations of and complications by the method became ap-
parent [4–6]. Some of these are very rare, reports are merely anec-
dotical and it is difﬁcult to develop an algorithm to understand,
anticipate and thereby prevent them [7–9]. One of these complica-
tions is aorto-bronchial or aorto-pulmonary ﬁstulation (ABPF) after
TEVAR presenting either as central airway (aorto-bronchial) or as
pulmonary parenchymal (aorto-pulmonary) ﬁstulation [10–13].
The aim of this study was to learn upon incidence, underlying
mechanisms and effectiveness of treatment strategies in patients
with ABPF after TEVAR.
METHODS
Patients
The records of 26 patients having developed ABPF after TEVAR
between 2001 and 2012 were analysed. The median age was 70
years [interquartile range (IQR): 60–77]. The cumulative caseload of
all 14 participating centres in this time period was 4680. Thirty-ﬁve
percent of patients were female and 42% had already undergone
any kind of previous open aortic surgery in various segments. The
primary underlying aortic pathology for TEVAR was thoracic aortic
aneurysm formation in 58% of patients.
Deﬁnition of aorto-bronchial or aorto-pulmonary
ﬁstulation
ABPF was deﬁned as any communication between the thoracic
aorta and the central airways or the pulmonary parenchyma
post-TEVAR. Patients where ABPF could have been already present
at the time of TEVAR or patients having native ABPF, either due to
the underlying aortic pathology or due to any other reasons, were
excluded.
Parameters
From the patients’ charts, individual clinical data, including any kind
of previous aortic surgery, underlying aortic pathology and extension
of aortic disease were collected. Procedural data included the index
TEVAR procedure, elective or emergent intervention, number of
prostheses, covered length and landing zones according to current
deﬁnitions. Additionally, detailed variables included the presence or
absence of mediastinal haematoma at the time of TEVAR, the time
interval between TEVAR and the diagnosis of ABPF, clinical symp-
toms, diagnostic modalities, treatment strategies, survival and causes
of death.
Statistical methods
Continuous data are presented as the median and IQR (range
from the 25th to the 75th percentile). Discrete data are given as
counts and percentages. In regard to the fortunate rare incidence
of this particular complication, we intentionally did not perform
extensive statistical comparisons between treatment groups or
forced data into regression analysis, as these procedures would
have resulted in extensive conﬁdence intervals of no obvious clin-
ical beneﬁt. However, despite the known clinical heterogeneity
between centres, we tried to answer two clinical questions by stat-
istical means by forming two groups of daily clinical interest: one,
the impact of the localization of a ﬁstula, and second, if patients
at risk might beneﬁt from a radical ‘one-stop-show’ approach.
Overall and ﬁstula-related survival were assessed via the method
by Kaplan and Meier. Calculations were performed with SPSS 20.0
for Mac OsX (IBM SPSS, Inc., NY, USA).
RESULTS
Incidence and prevalence
Out of 4680 patients, 26 patients with newly developed ABPF after
TEVAR were identiﬁed. The prevalence was 0.56% (range: 0.12–
3.31). The incidence was 0.40/1000 interventions/year (range:
0.08–2.36).
Patient demographics
Descriptive characteristics of the patient cohort are given in
Table 1. Eleven patients (42%) had already previous aortic repair
in various segments (Table 1). Atherosclerotic aneurysm formation
was the most frequent indication for TEVAR n = 15 (58%) (Table 1).
Index thoracic endovascular aortic repair
procedure and lesion diameter
Operative data of the ABPF cohort at the time of primary TEVAR
are given in Table 2. Half of the patients (n = 13) underwent emer-
gency TEVAR. Among the ABPF group, several different landing
zones were present, necessitating arch vessel overstenting in 35%
of cases (Table 2). The median covered length was 152 mm (IQR:
150–200). Eight patients (31%) had a mediastinal haematoma at
the time of TEVAR (Table 2). Of 15 patients having undergone
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TEVAR for atherosclerotic aneurysm formation, 7 underwent elect-
ive TEVAR. Their median aneurysm sac diameter was 9.2 cm. The
remaining patients underwent emergency TEVAR with a median
sac diameter of 5.6 cm.
Perioperative data
Acute kidney injury was seen in 2 patients (8%) and 8 patients
(31%) required prolonged intubation. Ten patients (38%) had
persisting endoleaks after TEVAR. The majority (80%) were type I
and type III endoleaks.
Presentation of aorto-bronchial or
aorto-pulmonary ﬁstulation
The median time interval between the initial TEVAR procedure
and the development of ABPF was 310 days (IQR: 28–1065). Three
patients developed simultaneous aorto-oesophageal ﬁstulation
(Table 3). Twenty-four patients (92%) had haemoptysis as leading
clinical sign. The diagnosis was conﬁrmed by computed tomog-
raphy (CT) in 23 patients (89%) with additional endoscopy in 13
patients (50%) (Table 3).
Diagnostic information and recognized
mechanisms of aorto-bronchial or
aorto-pulmonary ﬁstulation
Periaortic haematoma was the leading sign on CT scans (65%) fol-
lowed by periaortic air (39%) and lung haemorrhage (31%)
(Table 4). Fourteen patients (54%) developed central left bronchial
tree ﬁstulation, 11 patients (42%) developed pulmonary parenchy-
mal ﬁstulation and 1 patient (4%) developed tracheal ﬁstulation
(Table 4). External compression of the bronchial tree was the
recognized mechanism of ABPF in 13 patients (50%) whereas per-
sisting or newly developing endoleaks were common in contribut-
ing (Table 4). An ischaemic aetiology mainly due to overstenting
of feeding bronchial arteries was the recognized mechanism in 3
patients (12%) followed by inﬂammation and graft erosion in 4
patients (30%) each.
Management
Ten patients (39%) were deemed ﬁt for open repair. A conserva-
tive strategy was chosen in 5 patients (19%). Redo-TEVAR as the
Table 2: Initial interventional characteristics of the cohort
N overall = 26
Initial procedure
Emergency, (%) 13 (50)
Overstenting of arch vessels, n (%) 9 (35)
Previous vessel transposition, n (%) 4 (15)
Proximal bare metal springs, n (%) 21 (81)
Criado zone 0, n (%) 4 (15)
Criado zone 1, n (%) 2 (8)
Criado zone 2, n (%) 6 (23)
Criado zone 3, n (%) 12 (46)
Criado zone 4, n (%) 2 (8)
Stent coverage
Number of prostheses, median (range) 1 (1–2)
Coverage in mm, median (IQR) 152 (150–200)
Oversizing factor in percentages, median (range) 15 (7–20)
TEVAR extending below TA transition, n (%) 4 (15%)
Mediastinal haematoma at diagnosis, n (%) 8 (31%)
Intraoperative hypotension, n (%) 1 (4%)
Unless otherwise indicated, data are number (percentage).
IQR: interquartile range.
Table 1: Descriptive characteristics of the cohort
N overall = 26
Demographics
Age, median (IQR) 70 (60–77)
Female, n (%) 9 (35)
Chronic health conditions and risk factors
Hypertension, n (%) 20 (77)
Coronary artery disease, n (%) 6 (23)
Pulmonary disease, n (%) 8 (31)
Renal disease, n (%) 3 (12)
Previous CABG, n (%) 1 (4)
Previous aortic surgery/intervention, n (%) 11 (42)
Ascending aortic replacement, n (%) 2 (18)
Aortic arch replacement, n (%) 3 (27)
Descending aortic replacement, n (%) 5 (46)
Abdominal aortic replacement, n (%) 4 (36)
Underlying pathology
Aneurysm, n (%) 15 (58)
Chronic type B aortic dissection, n (%) 4 (15)
Penetrating atherosclerotic ulcer, n (%) 1 (4)
Anastomotic aneurysm, n (%) 1 (4)
Traumatic aortic injury, n (%) 4 (15)
Intramural haematoma, n (%) 1 (4)
Unless otherwise indicated, data are number (percentage).
IQR: interquartile range.
Table 3: Presentation of ABPF
N overall = 26
Timing and coincidence with ABPF
Days since initial TEVAR procedure, median (IQR) 310 (28–1065)
Simultaneous aorto-esophageal fistulation, n (%) 3 (12%)
Clinical presentation
Fever of unknown origin, n (%) 7 (27%)
Haematemesis, n (%) 15 (58%)
Haemoptysis, n (%) 24 (92%)
Shock, n (%) 6 (23%)
Pain, n (%) 4 (15%)
Dyspnoea, n (%) 7 (27%)
Other, n (%) 4 (15%)
Diagnostics
Computed tomography, n (%) 23 (89%)
MRI, n (%) 1 (4%)
Confirmation via endoscopy, n (%) 13 (50%)
Serum CRP (C-reactive protein) levels (mg/dl) 4.5 (0.8–7.8)
Unless otherwise indicated, data are number (percentage).
IQR: interquartile range.
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only treatment strategy was followed in 7 patients (27%). Bronchial
and/or pulmonary parenchymal repair without any aortic repair
was performed in 2 patients (8%) whereas bronchial and/or pul-
monary parenchymal repair in combination with redo-TEVAR was
done in another 2 patients (8%). Bronchial and/or pulmonary par-
enchymal repair, stent graft removal and aortic reconstruction
were performed in 8 patients (30%). Finally bronchial repair and
oesophagectomy and carotid-carotid bypass with tracheal stent-
ing were performed in 1 patient each (8%) (Table 5).
Outcome and follow-up
Overall survival was 39%. Twelve deaths (71%) were ABPF-related.
There was no difference in survival with regard to central bronchial
or pulmonary parenchymal ﬁstulations (33 vs 45%, log-rank
P = 0.55). There was a substantial difference in survival regarding
the conceptual treatment approach being signiﬁcantly better for a
radical approach than for a non-radical approach with regard to
overall survival (63 vs 32% and 63 vs 21% at 1 and 2 years, respect-
ively) as well as with regard to ﬁstula-related survival (63 vs 43% and
63 vs 43% at 1 and 2 years, respectively) (Fig. 1).
COMMENT
ABPF is a rare but highly lethal complication after TEVAR. The
leading mechanism behind ABPF seems to be a continuing external
compression of either the bronchial tree or left upper lobe paren-
chyma. In this setting, persisting or newly developing endoleak
formation seems to play a crucial role. Prognosis does not differ in
patients with central airway or pulmonary parenchymal ﬁstulation.
Radical bronchial or pulmonary parenchymal repair in combination
with stent graft removal and aortic reconstruction seems to be the
most durable treatment strategy.
The incidence of ABPF in this series was very low. This agrees
with previously published reports being mainly casuistics [10–13].
The percentage of patients who had previous aortic repair in this
series is high and underlines the multisegmental nature of the
disease. Atherosclerotic aneurysm formation was the leading indi-
cation for primary TEVAR in the majority of patients, followed by
chronic type B aortic dissection and traumatic aortic injury. This
reﬂects the distribution of acute and chronic thoracic aortic path-
ologies as is known in tertiary care centres.
Fifty percent of patients underwent initial emergency TEVAR.
As is known from previous European Registry of Endovascular
Aortic Repair Complications reports, the incidence of adjacent
organ injury is high in patients undergoing emergency TEVAR
[7–9]. Reasons are extensive mediastinal haematoma formation,
which may compress the oesophagus or the bronchial tree as well
as phases of continuing hypotension, thereby causing end-organ
ischaemia. As a consequence, staged mediastinal haematoma
evacuation to prevent secondary organ ﬁstulation has been
recommended previously [9].
The median time interval between initial TEVAR and the devel-
opment of ABPF was 310 days, suggesting a substantially slower
disease process than in aorto-oesophageal ﬁstulation (AOF) where
Table 4: Diagnostic information
N overall = 26
Findings by imaging
Periaortic haematoma, n (%) 17 (65%)
Periaortic air, n (%) 10 (39%)
Lung haemorrhage, n (%) 8 (31%)
Lung consolidation, n (%) 7 (27%)
Haematothorax, n (%) 5 (19%)
Bronchial wall erosion, n (%) 2 (8%)
Mediastinal haematoma, n (%) 4 (15%)
Localization of ABPF
Central left bronchial tree, n (%) 14 (54%)
Pulmonary parenchyma, n (%) 11 (42%)
Trachea, n (%) 1 (4%)
Recognized mechanism of ABPF
External compression of bronchial tree, n (%) 13 (50%)
Ischaemic, n (%) 3 (12%)
Inflammation, n (%) 4 (15%)
Graft erosion, n (%) 4 (15%)
Endoleak, n (%) 9 (35%)
Table 5: Management and outcome of ABPF
N overall = 26
Clinical assessment
Fit for open repair, n (%) 10 (39)
Management
Conservative, n (%) 5 (19)
TEVAR, n (%) 7 (27)
Bronchial or pulmonary parenchymal repair, no
aortic treatment, n (%)
2 (8)
Bronchial or pulmonary parenchymal repair,
TEVAR, n (%)
2 (8)
Bronchial or pulmonary parenchymal repair,
stent graft removal, aortic reconstruction, n (%)
8 (30)
Bronchial repair and oesophagectomy, n (%) 1 (4)
Carotideo-carotid bypass and tracheal stenting 1 (4)
Outcome
Survival, n (%) 10 (39)
Death related to ABPF, n (%) 12 (71)
Unless otherwise indicated, data are number (percentage).
Figure 1: Overall survival according to the approach.
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the time interval between initial TEVAR and the development
of AOF was 90 days [9]. The chronic pressure exertion on the
bronchus or the pulmonary parenchyma initially does not cause
the same injury as it might chronic pressure is exerted on the
oesophagus, which is an organ more susceptible to ischaemia.
Clinical signs of ABPF corresponded to what would be expected of
a leading sign of any kind of haemoptysis. Diagnosis was primarily
carried out by CT scanning with an additional 50% of patients
undergoing endoscopy for conﬁrmation.
Notably, the number of endoleaks after TEVAR was very high
with the majority being type I and type III. There seems to be a
direct correlation between aneurysmal sac extension and growth,
mediastinal haematoma formation and secondary central airway
or pulmonary parenchymal ﬁstulation. As a consequence, correct
indications, long landing zones and respecting anatomy in
patients scheduled for TEVAR cannot be overemphasized [4]. In
addition, we feel that it is important not to scotomize the third
option in treating patients with acute and chronic thoracic aortic
pathology if open surgery is not an option and TEVAR might
represent a trade-off, namely conservative therapy.
Although TEVAR has progressively evolved to become the
ﬁrst choice of thoracic aortic management for several clinical
scenarios, many of the current indications are not adequately
substantiated and proved. It is vital to verify if these extended
indications are reasonable and rational or if they are offered
as an option due to the inability to perform regular open surgery.
In addition, type I and type III endoleaks have to be regarded as
treatment failures, necessitating an urgent management that
should not be delayed [4].
However, external compression of the bronchial tree might also
occur without endoleak formation. In particular in patients with a
very large aneurysm diameter, per se, which already alters the
geometry of the bronchial tree, TEVAR might further increase
pressure exertion due to aneurysmal sac thrombosis with lack of
aortic wall elasticity. It was interesting to observe that aneurysm
sac diameter in elective patients undergoing TEVAR in this series
was impressively large, thereby substantiating this hypothesis. It
might be wise to reﬂect if in these clinical scenarios, an open sur-
gical approach might be the better strategy or to add a saccotomy
for decompression during the initial days after TEVAR.
Another factor exacerbating the process might be the additional
stenting of major airways already externally compressed. This
approach might increase the ischaemic burden of the bronchial
wall by exerting additional pressure from inside (Fig. 2) [13].
Oversizing might also play a role especially in patients where graft
erosion was the leading mechanism behind ABPF formation [12].
Oversizing is a matter of the underlying pathology, where acute
type B aortic dissection will require minimal oversizing and
atherosclerotic aneurysms will require more extensive oversizing.
Recommended ranges do merely represent approximations
learned from adverse events. In general, it might be stated that
any kind of oversizing >30% is inappropriate.
A variety of approaches to treat ABPF were chosen in this series
ranging from a conservative approach to an orthotopic full ﬁx of
the disease process with bronchial and/or pulmonary parenchy-
mal repair, stent graft removal and orthotopic or heterotopic
aortic reconstruction. Redo-TEVAR to seal the ﬁstulation from the
aortic side was a common treatment strategy as was the combin-
ation of redo-TEVAR and any kind of bronchial and/or pulmonary
parenchymal repair.
Interestingly, survival in patients with central airway and pul-
monary parenchymal ABPF did not differ. One would expect
pulmonary parenchymal ﬁstulas to be the more benign ones but
we did not observe that. There was a substantial difference with
regard to outcome according to the treatment strategy chosen.
Any approach either conservative or interventional with or
without bronchial and/or pulmonary parenchymal repair was
associated with poor outcome. Merely a radical surgical approach
with complete removal of the infected material, bronchial and/or
pulmonary parenchymal repair and any kind of orthotopic or het-
erotopic aortic reconstruction was associated with durable success
(Fig. 3) [14]. These ﬁndings substantiate the concept that a conser-
vative strategy in patients with graft infection is palliative, although
this is currently suggested otherwise [15].
Limitations and strengths
Without doubt, secondary organ injury is not limited to TEVAR
alone and secondary organ ﬁstulation also occurs after open
surgery. Patient number is limited and there is a selection bias in
this work as this approach to learn about the disease naturally
picks only a mere percentage of ABPFs occurring worldwide
within the last decade. Furthermore, the treatment strategy is
Figure 2: Left main bronchus before and after stenting due to compression
from the aneurysmal sac as a mechanism of aorto-bronchial ﬁstula formation—
axial view.
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strongly inﬂuenced by the suitability or non-suitability for a
radical approach and thereby precludes a full-ﬁx of the problem
in many of these patients. Nevertheless, this series was able to
present an initial systematic approach to learn about the inci-
dence, underlying mechanisms and effectiveness of treatment
strategies. Finally, to the best of our knowledge, this is the ﬁrst
report stratifying ABPF into central airway and pulmonary paren-
chymal lesions.
In sum, ABPF is a rare but highly lethal complication after TEVAR.
The leading mechanism behind ABPF seems to be a continuing
external compression of either the bronchial tree or left upper lobe
parenchyma. In this setting, persisting or newly developing endo-
leak formation seems to play a crucial role. Prognosis does not
differ in patients with central airway or pulmonary parenchymal
ﬁstulation. Radical bronchial or pulmonary parenchymal repair in
combination with stent graft removal and aortic reconstruction
seems to be the most durable treatment strategy.
Conﬂict of interest: none declared.
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